Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY1082439, an orally bioavailable, selective inhibitor of PI3Kα/β/δ, demonstrates high efficacy in inhibiting the growth of Pten-null prostate cancer [1][2]. Additionally, BAY1082439 is effective against mutated forms of PIK3CA.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,500 | |||
2 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 16,500 | |||
10 mg | 在庫あり | ¥ 28,000 | |||
25 mg | 在庫あり | ¥ 45,500 | |||
50 mg | 在庫あり | ¥ 85,000 | |||
100 mg | 在庫あり | ¥ 126,000 |
説明 | BAY1082439, an orally bioavailable, selective inhibitor of PI3Kα/β/δ, demonstrates high efficacy in inhibiting the growth of Pten-null prostate cancer [1][2]. Additionally, BAY1082439 is effective against mutated forms of PIK3CA. |
In vitro | BAY1082439 is a highly selective PI3Kα/α-balanced inhibitor. BAY1082439 (0.1-1 μM; 72 hours) is more effective than PI3Kα- and/or PI3Kβ-selective inhibitors in blocking PTEN-null prostate cancer cells[2]. BAY1082439 has an IC50 ratio of 1:3 in biochemical assays of PI3Kα (4.9 nM) vs. PI3Kα (15.0 nM), and >1000-fold selectivity against mTOR kinase[1]. |
In vivo | BAY1082439 (75 mg/kg; p.o.; daily for 4 weeks) is effective in preventing Pten-null prostate cancer progression[2]. |
分子量 | 494.54 |
分子式 | C25H30N6O5 |
CAS No. | 1375469-38-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BAY1082439 1375469-38-7 Apoptosis PI3K/Akt/mTOR signaling PI3K PTEN BAY 1082439 inhibit cancer oral Inhibitor BAY-1082439 forms Phosphoinositide 3-kinase mutated PIK3CA prostate inhibitor